propranolol has been researched along with Temporomandibular Joint Disorders in 12 studies
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.
Temporomandibular Joint Disorders: A variety of conditions affecting the anatomic and functional characteristics of the temporomandibular joint. Factors contributing to the complexity of temporomandibular diseases are its relation to dentition and mastication and the symptomatic effects in other areas which account for referred pain to the joint and the difficulties in applying traditional diagnostic procedures to temporomandibular joint pathology where tissue is rarely obtained and x-rays are often inadequate or nonspecific. Common diseases are developmental abnormalities, trauma, subluxation, luxation, arthritis, and neoplasia. (From Thoma's Oral Pathology, 6th ed, pp577-600)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The number of patients reporting a reduction in pain intensity rating was greater during propranolol treatment (P=0." | 9.14 | Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study. ( Diatchenko, L; Lim, PF; Maixner, W; McLean, SA; Slade, GD; Smith, SB; Tchivileva, IE, 2010) |
| "Propranolol is a nonselective β-adrenergic receptor antagonist that is efficacious in reducing facial pain." | 5.41 | ( Arbes, SJ; Fillingim, RB; Hadgraft, H; Ohrbach, R; Slade, GD; Tchivileva, IE; Willis, J, 2021) |
| "Propranolol's efficacy in reducing facial pain index was greater among the 104 migraineurs than the 95 non-migraineurs: For example, for the binary ≥ 30% reduction in facial pain index, odds ratios were 3." | 5.41 | Effect of comorbid migraine on propranolol efficacy for painful TMD in a randomized controlled trial. ( Arbes, SJ; Campbell, JH; Fillingim, RB; Giosia, MD; Hadgraft, H; Lim, PF; Ohrbach, R; Ribeiro-Dasilva, M; Slade, GD; Tchivileva, IE; Willis, J, 2021) |
| "The number of patients reporting a reduction in pain intensity rating was greater during propranolol treatment (P=0." | 5.14 | Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study. ( Diatchenko, L; Lim, PF; Maixner, W; McLean, SA; Slade, GD; Smith, SB; Tchivileva, IE, 2010) |
| "Propranolol is a nonselective beta-adrenergic receptor antagonist." | 2.94 | Efficacy and safety of propranolol for treatment of temporomandibular disorder pain: a randomized, placebo-controlled clinical trial. ( Arbes, SJ; Campbell, JH; Di Giosia, M; Fillingim, RB; Hadgraft, H; Herman-Giddens, M; James, R; Lim, PF; Ohrbach, R; Ribeiro-Dasilva, M; Slade, GD; Tchivileva, IE; Willis, J, 2020) |
| "The propranolol and SS group was significantly superior to the other groups on all other headache endpoints and in disability, in both ITT and PP analyses." | 2.78 | Treatment of comorbid migraine and temporomandibular disorders: a factorial, double-blind, randomized, placebo-controlled study. ( Bigal, ME; Camparis, CM; Castanharo, SM; Goncalves, DA; Lipton, RB; Speciali, JG; Ujikawa, LT, 2013) |
| "Propranolol has anti-inflammatory effects that contribute to its antinociceptive action in the TMJ of females." | 1.48 | Anti-inflammatory effects of propranolol in the temporomandibular joint of female rats and its contribution to antinociceptive action. ( Dias, EV; Parada, CA; Sartori, CR; Tambeli, CH; Teixeira, JM; Zanelatto, FB, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (16.67) | 29.6817 |
| 2010's | 4 (33.33) | 24.3611 |
| 2020's | 6 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cairns, BE | 1 |
| Sanders, AE | 1 |
| Slade, GD | 5 |
| Fillingim, RB | 4 |
| Ohrbach, R | 4 |
| Arbes, SJ | 4 |
| Tchivileva, IE | 5 |
| Hadgraft, H | 3 |
| Lim, PF | 3 |
| Di Giosia, M | 1 |
| Ribeiro-Dasilva, M | 2 |
| Campbell, JH | 2 |
| Willis, J | 3 |
| James, R | 1 |
| Herman-Giddens, M | 1 |
| Brignardello-Petersen, R | 1 |
| Giosia, MD | 1 |
| Zanelatto, FB | 1 |
| Dias, EV | 1 |
| Teixeira, JM | 1 |
| Sartori, CR | 1 |
| Parada, CA | 1 |
| Tambeli, CH | 1 |
| Goncalves, DA | 1 |
| Camparis, CM | 1 |
| Speciali, JG | 1 |
| Castanharo, SM | 1 |
| Ujikawa, LT | 1 |
| Lipton, RB | 1 |
| Bigal, ME | 1 |
| Light, KC | 1 |
| Bragdon, EE | 1 |
| Grewen, KM | 1 |
| Brownley, KA | 1 |
| Girdler, SS | 1 |
| Maixner, W | 2 |
| Smith, SB | 1 |
| Diatchenko, L | 1 |
| McLean, SA | 1 |
| Mujakperuo, HR | 1 |
| Watson, M | 1 |
| Morrison, R | 1 |
| Macfarlane, TV | 1 |
| Okamoto, K | 1 |
| Imbe, H | 1 |
| Tashiro, A | 1 |
| Kimura, A | 1 |
| Donishi, T | 1 |
| Tamai, Y | 1 |
| Senba, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of COMT (Catecholamine-O-methyltransferase) Genetic Polymorphisms on Response to Propranolol Therapy in Temporomandibular Disorder[NCT02437383] | Phase 2 | 200 participants (Actual) | Interventional | 2015-08-20 | Completed | ||
| Erenumab as a Therapeutic Approach for the Management of Painful Chronic Temporomandibular Disorders (TMD)[NCT05162027] | Phase 2 | 5 participants (Actual) | Interventional | 2022-04-01 | Terminated (stopped due to Low enrollment rate) | ||
| Analgesic Effects of Perioperative Propranolol Administration for Spine Surgery[NCT04421209] | Phase 2 | 0 participants (Actual) | Interventional | 2020-12-31 | Withdrawn (stopped due to No funding source) | ||
| The Effect of Sympathetic Dysfunction on Muscle Spindle Activity in Patients With Fibromyalgia Syndrome[NCT05704374] | 36 participants (Anticipated) | Interventional | 2023-11-02 | Not yet recruiting | |||
| Contribution of COMT Haplotypes in Propranolol Analgesic Efficacy for Treating Post-surgical Pain After Laparoscopic Hemicolectomy[NCT02511483] | Phase 2 | 10 participants (Actual) | Interventional | 2015-05-18 | Terminated (stopped due to Difficulty with recruitment) | ||
| Genetic Variants Associated With the Occurrence of Localized Low Back Pain or Low Back Pain With Widespread Pain Symptoms, and Their Response to Treatment With Duloxetine or Propranolol[NCT03364075] | Phase 2 | 10 participants (Actual) | Interventional | 2017-09-01 | Terminated (stopped due to Recruitment issue) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Average of 3 repeated measures taken with a 2-minute interval. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| Propranolol ER | -3.3 |
| Placebo | 1.0 |
Average of 3 repeated measures taken with a 2-minute interval. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | beats per minute (Least Squares Mean) |
|---|---|
| Propranolol ER | -3.9 |
| Placebo | 1.5 |
Measured at TMD exam. A higher value means a better outcome. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | mm (Least Squares Mean) |
|---|---|
| Propranolol ER | -0.3 |
| Placebo | -0.8 |
Measured at TMD exam. A higher value means a better outcome. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | mm (Least Squares Mean) |
|---|---|
| Propranolol ER | -0.9 |
| Placebo | -1.2 |
Measured at TMD exam. A higher value means a better outcome. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | mm (Least Squares Mean) |
|---|---|
| Propranolol ER | 4.5 |
| Placebo | 1.4 |
Pressure values, measured in kilopascals, from up to 5 experimental pressure stimuli, bilaterally applied to the area of lateral epicondyle, will be averaged to obtain a single pressure pain threshold value per anatomical site. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | kPa (Least Squares Mean) |
|---|---|
| Propranolol ER | 41.4 |
| Placebo | 22.7 |
Pressure values, measured in kilopascals, from up to 5 experimental pressure stimuli, bilaterally applied to the area of masseter muscle, will be averaged to obtain a single pressure pain threshold value per anatomical site. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/- 7)
| Intervention | kPa (Least Squares Mean) |
|---|---|
| Propranolol ER | 38.3 |
| Placebo | 29.3 |
Pressure values, measured in kilopascals (kPa), from up to 5 experimental pressure stimuli, bilaterally applied to the area of temporalis muscle, are averaged to obtain a single pressure pain threshold value per anatomical site. The range is 0-500 kPa and a higher value means a better outcome. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | kPa (Least Squares Mean) |
|---|---|
| Propranolol ER | 41.8 |
| Placebo | 38.4 |
Pressure values, measured in kilopascals, from up to 5 experimental pressure stimuli, bilaterally applied to the area of temporomandibular joint, will be averaged to obtain a single pressure pain threshold value per anatomical site. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | kPa (Least Squares Mean) |
|---|---|
| Propranolol ER | 36.8 |
| Placebo | 25.3 |
Pressure values, measured in kilopascals, from up to 5 experimental pressure stimuli, bilaterally applied to the area of trapezius muscle, will be averaged to obtain a single pressure pain threshold value per anatomical site. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | kPa (Least Squares Mean) |
|---|---|
| Propranolol ER | 64.1 |
| Placebo | 63.3 |
Average of 3 repeated measures taken with a 2-minute interval. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| Propranolol ER | -3.6 |
| Placebo | 1.3 |
"The HIT-6 contains 6 items and assesses headache-related disability by the frequency of daily activity limitations ranging from never to always. The 6 item scores are summed to yield a global score ranging from 36 to 78. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Propranolol ER | -5.1 |
| Placebo | -3.1 |
"The HADS is a 14-item assessment of anxiety (7 items) and depression (7 items) using the relative frequency of symptoms over the past week, rated on a 4-point scale ranging from 0 = not at all to 3 = very often indeed. Responses are summed to provide separate scores for anxiety and depression with a range from 0 to 21. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Propranolol ER | -1.3 |
| Placebo | -0.7 |
"The HADS is a 14-item assessment of anxiety (7 items) and depression (7 items) using the relative frequency of symptoms over the past week, rated on a 4-point scale ranging from 0 = not at all to 3 = very often indeed. Responses are summed to provide separate scores for anxiety and depression with a range from 0 to 21. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Propranolol ER | -1.0 |
| Placebo | -0.6 |
"The JFLS contains 20 items that measure limitations across mastication, vertical jaw mobility, and verbal/emotional expression rated on a 0-10 scale where 0 = no limitation and 10 = severe limitation. The Global Score is computed as the mean response for all items and ranges from 0 to 10. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Propranolol ER | -1.1 |
| Placebo | -0.8 |
"The PSS assesses the frequency of 14 sources of stress on a scale from 0 = never to 4 = very often. The item scores are summed to yield a global score ranging from 0 to 56. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Propranolol ER | -2.6 |
| Placebo | -1.9 |
The PSQI has 19 items grouped into 7 component scores, each weighted equally on a 0-3 scale, The 7 component scores are summed to yield a global PSQI score, which has a range of 0-21. A higher score means a worse outcome. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Propranolol ER | -0.7 |
| Placebo | -1.0 |
"The SF-12v2 contains 7 questions assessing 8 domains of functioning and well-being rated from: excellent to poor (for general health); yes, limited a lot to no, not limited at all (for functional level); and all of the time to none of the time (for emotional state). These 8 domains can be further summarized into a physical component summary (PCS) and a mental component summary (MCS). The range for each component is 0-100 and a higher score means a better outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Propranolol ER | 3.6 |
| Placebo | 2.8 |
"The SF-12v2 contains 7 questions assessing 8 domains of functioning and well-being rated from: excellent to poor (for general health); yes, limited a lot to no, not limited at all (for functional level); and all of the time to none of the time (for emotional state). These 8 domains can be further summarized into a physical component summary (PCS) and a mental component summary (MCS). summary (MCS). The range for each component is 0-100 and a higher score means a better outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Propranolol ER | 1.2 |
| Placebo | 0.3 |
"The SF-McGill Pain Questionnaire contains 4 affective descriptors rated on a 0-3 scale where 0 = none, 1 = mild, 2 = moderate, and 3 = severe. The item scores are summed to yield a total score ranging from 0 to 12. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Propranolol ER | -2.9 |
| Placebo | -3.1 |
"Self-reported present intensity of facial pain at the moment of assessment scored on a descriptive scale where 1 = no pain' and 6 = excruciating pain. A higher score means worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Propranolol ER | -0.9 |
| Placebo | -0.7 |
"The SF-McGill Pain Questionnaire contains 11 sensory descriptors rated on a 0-3 scale where 0 = none, 1 = mild, 2 = moderate, and 3 = severe. The item scores are summed to yield a total score ranging from 0 to 33. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Propranolol ER | -1.9 |
| Placebo | -1.6 |
"Self-reported average facial pain duration for the last week scored on 0-100 percentage scale where percent = percent of waking day you had facial pain. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Propranolol ER | -23.6 |
| Placebo | -21.6 |
"Self-reported average facial pain intensity for the last week scored on 0-100 numerical rating scale where 0 = no pain and 100 = the most intense pain imaginable. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Propranolol ER | -18.2 |
| Placebo | -15.8 |
"Self-reported average fatigue for the last week scored on 0-100 numerical rating scale where 0 = no fatigue and 100 = the greatest imaginable. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Propranolol ER | -12.0 |
| Placebo | -11.4 |
"The SCL-90R Somatization Scale is a 12-item assessment of somatic symptom distress over the past 7 days rated from 0 = not at all to 4 = extremely. The scale score is computed as the mean for all items. The score range is from 0 to 4. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Propranolol ER | -0.2 |
| Placebo | -0.2 |
"Weekly mean pain duration computed as the arithmetic mean of daily pain duration values during the week prior to randomization and prior to each study visit. Daily pain duration is measured on 0-100 percentage scale where percent = percent of waking day you had facial pain as reported in the Daily Symptom Diary. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Propranolol ER | -17.9 |
| Placebo | -16.6 |
"Weekly mean pain index computed as the arithmetic mean of daily pain index values during the week prior to randomization and prior to each study visit. Daily pain index is computed as pain intensity (0-100 numeric rating scale where 0 = no pain and 100 = the most intense pain imaginable) multiplied by pain duration (0-100 percentage scale where percent = percent of waking day you had facial pain) as reported in the Daily Symptom Diary and divided by 100. The pain index range is from 0 to 100. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Propranolol ER | -13.9 |
| Placebo | -12.1 |
"Weekly mean pain intensity computed as the arithmetic mean of daily pain intensity values during the week prior to randomization and prior to each study visit. Daily pain intensity is measured on 0-100 numeric rating scale where 0 = no pain and 100 = the most intense pain imaginable) as reported in the Daily Symptom Diary. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Propranolol ER | -17.1 |
| Placebo | -13.6 |
Temperature values, measured in degrees Celsius, from 4 examiner-applied contact heat stimuli will be averaged to measure the experimental thermal pain threshold (temperature at which pain is first perceived). The range was 32-50 degrees Celsius and a higher value means a better outcome. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | degrees Celsius (Least Squares Mean) |
|---|---|
| Propranolol ER | 1.3 |
| Placebo | 0.5 |
Temperature values, measured in degrees Celsius, from 4 examiner-applied contact heat stimuli will be averaged to measure the experimental thermal pain tolerance (temperature at which pain can no longer be tolerated). The range was 32-50 degrees Celsius and a higher value means a better outcome. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | degrees Celsius (Least Squares Mean) |
|---|---|
| Propranolol ER | 0.5 |
| Placebo | 0.4 |
"Weekly mean pain index computed as the arithmetic mean of daily pain index values during the week prior to randomization and prior to each study visit. Daily pain index is computed as pain intensity (0-100 numeric rating scale where 0 = no pain and 100 = the most intense pain imaginable) multiplied by pain duration (0-100 percentage scale where percent = percent of waking day you had facial pain) as reported in the Daily Symptom Diary, divided by 100. The pain index range is from 0 to 100. A higher score means a worse outcome. The pain index was stratified per number of catechol-O-methyltransferase (COMT) Low Pain Sensitive (LPS) haplotypes." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | units on a scale (Least Squares Mean) | ||
|---|---|---|---|
| 0 LPS haplotypes | 1 LPS haplotype | 2 LPS haplotypes | |
| Placebo | -12.3 | -13.2 | -2.5 |
| Propranolol ER | -14.2 | -12.2 | -15.2 |
"Weekly mean pain index computed as the arithmetic mean of daily pain index values during the week prior to randomization and prior to each study visit. Daily pain index is computed as pain intensity (0-100 numeric rating scale where 0 = no pain and 100 = the most intense pain imaginable) multiplied by pain duration (0-100 percentage scale where percent = percent of waking day you had facial pain) as reported in the Daily Symptom Diary, divided by 100. The pain index range is from 0 to 100. A higher score means a worse outcome. The pain index was stratified per number of catechol-O-methyltransferase (COMT) valine alleles at single nucleotide polymorphism (SNP) rs4680." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | units on a scale (Least Squares Mean) | ||
|---|---|---|---|
| 0 valine alleles | 1 valine allele | 2 valine alleles | |
| Placebo | -13.9 | -13.1 | -9.7 |
| Propranolol ER | -14.2 | -13.9 | -14.3 |
2 reviews available for propranolol and Temporomandibular Joint Disorders
| Article | Year |
|---|---|
The contribution of autonomic mechanisms to pain in temporomandibular disorders: A narrative review.
Topics: Adrenergic Agonists; Analgesics; Antidepressive Agents; Autonomic Nervous System; Botulinum Toxins, | 2022 |
Pharmacological interventions for pain in patients with temporomandibular disorders.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticonvulsants; Benzodiazepines; Capsaicin; Facial Pain; G | 2010 |
6 trials available for propranolol and Temporomandibular Joint Disorders
| Article | Year |
|---|---|
Efficacy and safety of propranolol for treatment of temporomandibular disorder pain: a randomized, placebo-controlled clinical trial.
Topics: Alcoholism; Double-Blind Method; Female; Humans; Propranolol; Temporomandibular Joint Disorders; Tre | 2020 |
Efficacy and safety of propranolol for treatment of temporomandibular disorder pain: a randomized, placebo-controlled clinical trial.
Topics: Alcoholism; Double-Blind Method; Female; Humans; Propranolol; Temporomandibular Joint Disorders; Tre | 2020 |
Efficacy and safety of propranolol for treatment of temporomandibular disorder pain: a randomized, placebo-controlled clinical trial.
Topics: Alcoholism; Double-Blind Method; Female; Humans; Propranolol; Temporomandibular Joint Disorders; Tre | 2020 |
Efficacy and safety of propranolol for treatment of temporomandibular disorder pain: a randomized, placebo-controlled clinical trial.
Topics: Alcoholism; Double-Blind Method; Female; Humans; Propranolol; Temporomandibular Joint Disorders; Tre | 2020 |
Topics: Catechol O-Methyltransferase; Facial Pain; Genotype; Humans; Polymorphism, Single Nucleotide; Propra | 2021 |
Effect of comorbid migraine on propranolol efficacy for painful TMD in a randomized controlled trial.
Topics: Adolescent; Adult; Aged; Autonomic Nervous System; Chronic Pain; Double-Blind Method; Facial Pain; F | 2021 |
Treatment of comorbid migraine and temporomandibular disorders: a factorial, double-blind, randomized, placebo-controlled study.
Topics: Adrenergic beta-Antagonists; Adult; Analysis of Variance; Comorbidity; Double-Blind Method; Facial P | 2013 |
Adrenergic dysregulation and pain with and without acute beta-blockade in women with fibromyalgia and temporomandibular disorder.
Topics: Adrenergic beta-Antagonists; Adult; Cross-Over Studies; Double-Blind Method; Epinephrine; Female; Fi | 2009 |
Adrenergic dysregulation and pain with and without acute beta-blockade in women with fibromyalgia and temporomandibular disorder.
Topics: Adrenergic beta-Antagonists; Adult; Cross-Over Studies; Double-Blind Method; Epinephrine; Female; Fi | 2009 |
Adrenergic dysregulation and pain with and without acute beta-blockade in women with fibromyalgia and temporomandibular disorder.
Topics: Adrenergic beta-Antagonists; Adult; Cross-Over Studies; Double-Blind Method; Epinephrine; Female; Fi | 2009 |
Adrenergic dysregulation and pain with and without acute beta-blockade in women with fibromyalgia and temporomandibular disorder.
Topics: Adrenergic beta-Antagonists; Adult; Cross-Over Studies; Double-Blind Method; Epinephrine; Female; Fi | 2009 |
Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study.
Topics: Adrenergic beta-Antagonists; Adult; Catechol O-Methyltransferase; Cross-Over Studies; Double-Blind M | 2010 |
Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study.
Topics: Adrenergic beta-Antagonists; Adult; Catechol O-Methyltransferase; Cross-Over Studies; Double-Blind M | 2010 |
Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study.
Topics: Adrenergic beta-Antagonists; Adult; Catechol O-Methyltransferase; Cross-Over Studies; Double-Blind M | 2010 |
Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study.
Topics: Adrenergic beta-Antagonists; Adult; Catechol O-Methyltransferase; Cross-Over Studies; Double-Blind M | 2010 |
Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study.
Topics: Adrenergic beta-Antagonists; Adult; Catechol O-Methyltransferase; Cross-Over Studies; Double-Blind M | 2010 |
Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study.
Topics: Adrenergic beta-Antagonists; Adult; Catechol O-Methyltransferase; Cross-Over Studies; Double-Blind M | 2010 |
Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study.
Topics: Adrenergic beta-Antagonists; Adult; Catechol O-Methyltransferase; Cross-Over Studies; Double-Blind M | 2010 |
Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study.
Topics: Adrenergic beta-Antagonists; Adult; Catechol O-Methyltransferase; Cross-Over Studies; Double-Blind M | 2010 |
Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study.
Topics: Adrenergic beta-Antagonists; Adult; Catechol O-Methyltransferase; Cross-Over Studies; Double-Blind M | 2010 |
Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study.
Topics: Adrenergic beta-Antagonists; Adult; Catechol O-Methyltransferase; Cross-Over Studies; Double-Blind M | 2010 |
Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study.
Topics: Adrenergic beta-Antagonists; Adult; Catechol O-Methyltransferase; Cross-Over Studies; Double-Blind M | 2010 |
Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study.
Topics: Adrenergic beta-Antagonists; Adult; Catechol O-Methyltransferase; Cross-Over Studies; Double-Blind M | 2010 |
Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study.
Topics: Adrenergic beta-Antagonists; Adult; Catechol O-Methyltransferase; Cross-Over Studies; Double-Blind M | 2010 |
Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study.
Topics: Adrenergic beta-Antagonists; Adult; Catechol O-Methyltransferase; Cross-Over Studies; Double-Blind M | 2010 |
Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study.
Topics: Adrenergic beta-Antagonists; Adult; Catechol O-Methyltransferase; Cross-Over Studies; Double-Blind M | 2010 |
Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study.
Topics: Adrenergic beta-Antagonists; Adult; Catechol O-Methyltransferase; Cross-Over Studies; Double-Blind M | 2010 |
4 other studies available for propranolol and Temporomandibular Joint Disorders
| Article | Year |
|---|---|
Effect of Treatment Expectation on Placebo Response and Analgesic Efficacy: A Secondary Aim in a Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Analgesics; Humans; Middle Aged; Myalgia; Placebo Effect; Propranolol; Rand | 2020 |
Patients with temporomandibular pain who receive propranolol are more likely to experience pain reduction than those who receive a placebo.
Topics: Humans; Pain; Propranolol; Somatoform Disorders; Temporomandibular Joint Disorders | 2020 |
Anti-inflammatory effects of propranolol in the temporomandibular joint of female rats and its contribution to antinociceptive action.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Analgesics; Animals; Anti-Inflammatory Ag | 2018 |
The role of peripheral 5HT2A and 5HT1A receptors on the orofacial formalin test in rats with persistent temporomandibular joint inflammation.
Topics: Animals; Arthralgia; Arthritis; Disease Models, Animal; Dose-Response Relationship, Drug; Facial Pai | 2005 |